消息面上，药明合联发布公告，宣布公司与药明生物技术于9月3日签署了认购协议，约定发售2413万股 新股份，占公司截至最后实际可行日期已发行股本的约1.96%。认购事项完成后，药明生物技术的持股 比例将由48.81%增至50.74%，而其他公众股东的持股比例将由28.76%下降至28.21%。 药明合联(02268)早盘涨超7%，高见75.8港元再创新高。截至发稿，涨4.97%，报73.9港元，成交额2.01 亿港元。 公告中提到，认购事项所得款项净额约为14.14亿港元，计划用于扩展集团的服务能力和产能，其中约 90%将用于生物偶联药物及相关产品的生产能力扩展，约10%将用于日常运营资金需求。 ...

公告中提到，认购事项所得款项净额约为14.14亿港元，计划用于扩展集团的服务能力和产能，其中约 90%将用于生物偶联药物及相关产品的生产能力扩展，约10%将用于日常运营资金需求。 智通财经APP获悉，药明合联(02268)早盘涨超7%，高见75.8港元再创新高。截至发稿，涨4.97%，报 73.9港元，成交额2.01亿港元。 消息面上，药明合联发布公告，宣布公司与药明生物技术于9月3日签署了认购协议，约定发售2413万股 新股份，占公司截至最后实际可行日期已发行股本的约1.96%。认购事项完成后，药明生物技术的持股 比例将由48.81%增至50.74%，而其他公众股东的持股比例将由28.76%下降至28.21%。 ...

（股份代號：2268） WUXI XDC CAYMAN INC. 藥明合聯生物技術有限公司* （於開曼群島註冊成立的有限公司） 與 本 代 表 委 任 表 格 有 關 的 股 份 數 目 （附 註1） 將 於2025年10月9日（星 期 四）舉 行 的 股 東 特 別 大 會 代 表 委 任 表 格 本 人╱我 們 （附 註2） 地 址 為 為 本 人╱我 們 的 受 委 代 表，出 席 本 公 司 謹 訂 於2025年10月9日（星 期 四）上 午 十 時 正 假 座 中 國 江 蘇 省 無 錫 市 新 吳 區 新 華 路5 號 亞 朵 酒 店 舉 行 的 股 東 特 別 大 會（「股 東 特 別 大 會」）（及 其 任 何 續 會），以 代 表 本 人╱我 們 按 下 列 指 示 行 事 及 表 決。 請 在 適 當 欄 內 填 上「 」號，以 表 示 閣 下 的 投 票 意 願 （附 註4） 。 | | | 普 通 決 議 案 贊 成 反 對 | | --- | --- | --- | | 1. | 動 議： | | | | (a) | | | | | 批准、確認及追認本公司（作為發行人）與藥明生物技術 ...

股 東 特 別 大 會 通 知 茲 通 知 藥 明 合 聯 生 物 技 術 有 限 公 司*（「本 公 司」）謹 訂 於2025年10月9日（星 期 四） 上 午 十 時 正 假 座 中 國 江 蘇 省 無 錫 市 新 吳 區 新 華 路5號 亞 朵 酒 店 舉 行 股 東 特 別 大 會（「大 會」），藉 以 考 慮 及 酌 情 通 過（不 論 有 否 修 訂）以 下 決 議 案 為 本 公 司 普 通 決 議 案。除 非 另 有 界 定，本 通 知 所 用 詞 彙 與 本 公 司 日 期 為2025年9月22日 的 通 函 所 界 定 者 具 有 相 同 涵 義。 普 通 決 議 案 「動 議： – 1 – 1. (i) 批准、確認及追認本公司（作為發行人）與藥明生物技術有限公司（「認購人」） （作為認購人）所訂立日期為2025年9月3日的認購協議（「認購協議」，註有「A」 字 樣 之 副 本 已 提 呈 股 東 特 別 大 會，且 經 股 東 特 別 大 會 主 席 簽 署 以 資 識 別）（據 此，本 公 司 已 有 條 件 同 意 向 認 購 人 發 行 及 配 發 而 認 購 人 已 有 條 件 ...

此 乃 要 件 請 即 處 理 閣 下 對 本 通 函 任 何 方 面 或 應 採 取 的 行 動 如 有 任 何 疑 問，應 諮 詢 股 票 經 紀 或 其 他 註 冊 證 券 交 易 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 出 售 或 轉 讓 名 下 所 有 藥 明 合 聯 生 物 技 術 有 限 公 司*的 股 份，應 立 即 將 本 通 函 連 同 隨 附 的 代 表 委 任 表 格 送 交 買 主 或 承 讓 人、或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理 人，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 通 函 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 WUXI XDC CA ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） 藥 明 合 聯 生 物 技 術 有 限 公 司* （股份代號：2268） 本公司預期將於2025年10月9 日（ 星期四 ）召開股東特別大會，以供獨立股東考慮 及酌情批准認購協議及其項下擬進行的交易以及特別授權。鑒於預計舉行的股東 特別大會及為釐定股東出席股東特別大會並於會上投票的權利，本公司將於2025 年10 月6 日（ 星期一 ）至2025 年10月 9 日（ 星期四 ）止（ 包 括首尾兩 天 ）暫停辦 理股份 過戶登記手續，在此期間概不會辦理任何股份過戶登記。 為符合資格出席股東特別大會並於會上投票，所有過戶文件連同有關股票必須在 不遲於2025年10月3日（ 星期五 ）下午四時三十分送達本公司的香港股份過戶登記 處 香 港 中 央 證券 登 記 有 限 ...

Group 1 - As of September 19, 93 stocks reached their 52-week highs, with Huake Intelligent Investment (01140), Xincheng Power (01148), and Huashang Energy (00206) leading the increase rates at 22.30%, 20.00%, and 17.65% respectively [1] - The closing prices for the top three stocks that reached new highs are Huake Intelligent Investment at 0.170, Xincheng Power at 0.300, and Huashang Energy at 0.305 [1] - Other notable stocks that reached new highs include Handa Fu Holdings (01348) with a high rate of 16.89% and Meijiehui Holdings (01389) at 13.75% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Shanga Holdings (00412) experiencing the largest decline at -34.98%, followed by Huaying Construction (01582) at -21.47% [3] - The closing price for Shanga Holdings is 3.360, while Huaying Construction closed at 0.360 [3] - Other stocks with significant declines include China Information Technology Equity (08568) at -17.74% and Tai Hing Properties (00277) at -11.90% [3]

Core Viewpoint - The Hong Kong innovative drug sector has rebounded significantly after a previous decline, with several companies experiencing substantial stock price increases, indicating a positive market sentiment despite concerns over potential restrictions from the U.S. on Chinese innovative drugs [2][3][4]. Group 1: Market Performance - After a drop of approximately 3.82% in the innovative drug sector, stocks like Nocera (09969.HK) surged over 14%, nearing historical highs, while others like Hutchison China MediTech (00013.HK) and Zai Lab (09688.HK) also saw significant gains [3][4]. - The A-share market mirrored this trend, with the innovative drug index rising by 1.08%, and notable stocks like Nocera-U (688428.SH) increasing over 12% [3][4]. - Since April 9, the A-share and Hong Kong innovative drug sectors have shown strong growth, with the A-share index up 62% and the Hong Kong index up over 130% as of September 12 [4]. Group 2: Company Developments - Several pharmaceutical companies have acknowledged the rumors regarding U.S. restrictions but believe these do not currently impact the prospects for Chinese innovative drugs entering international markets [4][6]. - Key catalysts for stock price increases include recent approvals for new drugs, such as Nocera's approval for a treatment in Singapore, and positive earnings reports from companies like BeiGene and Innovent Biologics [6][11]. Group 3: Financial Performance - The innovative drug sector is entering a new cycle driven by profitability, with many companies reporting significant revenue growth. For instance, 62% of companies in the sector reported positive revenue growth, and 28% achieved positive net profit [8][11]. - In the first half of 2025, the total revenue for 50 Hong Kong-listed innovative drug companies reached 44.9 billion HKD, a year-on-year increase of 31.48%, with net profits rising by 128.4% [8][11]. - Major companies like BeiGene and Innovent Biologics have reported revenue growth exceeding 40%, marking a significant turnaround in their financial performance [11][12]. Group 4: Policy and Regulatory Environment - Recent policy changes have been favorable for the innovative drug sector, with the National Medical Products Administration optimizing clinical trial review processes to support the development of innovative drugs [3][13]. - The introduction of mechanisms to reduce supply disruption risks in drug procurement policies is expected to benefit innovative drug companies by allowing for a broader evaluation of production quality and supply capabilities [13].

Core Viewpoint - The Hong Kong innovative drug sector has rebounded significantly after a previous decline, with major companies like Nocare and Hutchison Medipharma seeing substantial stock price increases, indicating a positive market sentiment despite concerns over potential restrictions from the U.S. on Chinese innovative drugs [3][5][6]. Market Performance - Following a drop of approximately 3.82% in the innovative drug sector, the market saw a recovery with notable gains: Nocare up over 14%, Hutchison Medipharma up over 11%, and others also showing significant increases [4][5]. - The A-share market mirrored this trend, with the innovative drug index rising by 1.08% [5]. - Since April 9, the A-share and Hong Kong innovative drug sectors have shown strong performance, with the A-share index up 62% and the Hong Kong index up over 130% as of September 12 [6]. Company Performance - A total of 17 innovative drug companies have reached new stock price highs in 2025, with significant increases observed in companies like Baijie Shenzhou and Hengrui Medicine [6]. - Companies that had previously seen their stock prices halved from 2021 to 2024 have experienced substantial recoveries, with some stocks increasing by over 250% in A-shares and over 650% in Hong Kong [7][8]. Financial Results - The innovative drug sector is entering a new profit-driven cycle, with 62% of companies reporting revenue growth and 28% achieving positive net profits in the first half of 2025 [11][16]. - Notably, Baijie Shenzhou and Xinda Biotech achieved profitability for the first time in the first half of 2025, with revenue growth rates exceeding 40% for several leading companies [17]. - The total revenue for 50 Hong Kong innovative drug companies reached 44.9 billion HKD in the first half of 2025, marking a year-on-year increase of 31.48% [11]. Policy and Market Drivers - The recent approval of clinical trial applications for innovative drugs by the National Medical Products Administration is expected to enhance the development of the sector [5]. - The overseas licensing of innovative drugs has seen a significant increase, with total amounts reaching 94.3 billion USD by September 2025, surpassing the total for 2024 [18]. - Policy changes are increasingly favorable for the sector, with recent adjustments to procurement policies aimed at reducing supply chain risks and promoting quality over price [19].

Core Viewpoint - The Hong Kong innovative drug sector has rebounded significantly after a previous decline, with major companies experiencing substantial stock price increases, indicating a positive market sentiment despite concerns over potential restrictions from the U.S. on Chinese innovative drugs [1][2][3]. Group 1: Market Performance - The Hong Kong innovative drug index (HK1105) fell approximately 3.82% due to market rumors but has since rebounded, with notable stocks like Innovent Biologics (09969.HK) rising over 12% to nearly historical highs [2][3]. - The A-share innovative drug index (BK1106) also saw a rise of 1.08%, with several companies achieving significant stock price increases, including Innovent Biologics-U (688428.SH) which rose over 12% [2][3]. - Since April 9, the A-share and Hong Kong innovative drug sectors have shown strong performance, with the A-share index increasing by 62% and the Hong Kong index by over 130% [3]. Group 2: Company Developments - Companies like Innovent Biologics and BeiGene are expected to reach profitability by 2025, with many biotech firms anticipated to enter a profitable cycle due to improved industrial capabilities and product line expansions [1][3]. - Recent approvals, such as Innovent Biologics' drug for treating relapsed/refractory marginal zone lymphoma, have acted as key catalysts for stock price increases [5]. - A total of 17 innovative drug companies are projected to reach new stock price highs by 2025, with significant gains observed in both A-share and Hong Kong markets [3]. Group 3: Financial Performance - The innovative drug sector is expected to see a total revenue of 449 billion yuan in the first half of 2025, reflecting a year-on-year growth of 31.48%, with 62% of companies reporting positive revenue growth [6][9]. - Notably, companies like BeiGene and Innovent Biologics have reported over 40% year-on-year revenue growth, marking a significant turnaround in profitability for many firms [11][12]. - The overseas licensing agreements for Chinese innovative drugs have reached a total of 943 billion USD, significantly surpassing the previous year's total, indicating strong international market potential [12][14]. Group 4: Policy and Regulatory Environment - Recent regulatory changes have favored the innovative drug sector, with policies aimed at optimizing clinical trial approvals and reducing supply chain risks, which are expected to benefit innovative drug companies [6][14]. - The introduction of mechanisms to support non-winning bidders in drug procurement is anticipated to enhance the market environment for innovative drugs, moving away from a solely price-based evaluation [14].